Overview Open Label Continuation Study in Moderate to Severe Psoriasis Status: Completed Trial end date: 2011-10-01 Target enrollment: Participant gender: Summary The purpose of this study is to evaluate long term safety, efficacy and tolerability of ABT-874 in adults with moderate to severe psoriasis. Phase: Phase 3 Details Lead Sponsor: AbbVie (prior sponsor, Abbott)